We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Analysis shows that autoantibodies may correlate with dermatologic events in patients receiving enfortumab vedotin, indicating potential biomarkers for treatment responses.
Baseline characteristics of patients with vs. without EVDEs (cohort B).
No takes yet. Share an insight, caveat, or question.
Vlachou et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: